The 5 analysts offering 12-month price forecasts for Immunovant Inc have a median target of 32.00, with a high estimate of 36.00 and a low estimate of 26.00. The median estimate represents a +15.15% increase from the last price of 27.79.
The current consensus among 5 polled investment analysts is to Buy stock in Immunovant Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.33
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.